# Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

> **NCT03130790** · PHASE2,PHASE3 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Varlitinib
- **DRUG:** mFOLFOX6
- **DRUG:** Placebo
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT03130790
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-31
- **Primary completion:** 2018-12-20
- **Final completion:** 2019-02-22
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130790, "Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03130790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*